Highbridge Capital Management

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company's development pipeline includes several therapeutic candidates, such as BL-8040, a peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization. Another key candidate is AGI-134, an immuno-oncology agent aimed at solid tumors. Additionally, BioLineRx has developed BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company has established collaborations with prominent organizations, including MSD for cancer immunotherapy, MD Anderson Cancer Center to explore the combination of BL-8040 with KEYTRUDA in pancreatic cancer, and Genentech Inc. for studies involving BL-8040 and TECENTRIQ in solid tumors. Founded in 2003, BioLineRx is focused on addressing unmet medical needs and improving existing therapies in the pharmaceutical market.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Invacare Corporation is a leading manufacturer and distributor of medical equipment focused on home health care and long-term care markets globally. Established in 1885 and headquartered in Elyria, Ohio, Invacare designs, manufactures, and distributes a wide range of products that assist individuals with mobility, respiratory needs, and essential daily activities. The company offers mobility solutions, including power and manual wheelchairs, as well as seating and positioning products. Its lifestyle offerings encompass pressure-relieving overlays, mattress systems, and personal care items. Additionally, Invacare provides respiratory therapy equipment, such as stationary and portable oxygen concentrators, alongside healthcare furnishings for long-term care settings. The company primarily sells its products through home medical equipment providers, residential care operators, and government health services, utilizing various distribution channels including retail and e-commerce. Invacare is committed to supporting individuals with diverse medical conditions, thereby promoting recovery and active lifestyles.

Invacare Corporation is a leading manufacturer and distributor of medical equipment focused on home health care and long-term care markets globally. Established in 1885 and headquartered in Elyria, Ohio, Invacare designs, manufactures, and distributes a wide range of products that assist individuals with mobility, respiratory needs, and essential daily activities. The company offers mobility solutions, including power and manual wheelchairs, as well as seating and positioning products. Its lifestyle offerings encompass pressure-relieving overlays, mattress systems, and personal care items. Additionally, Invacare provides respiratory therapy equipment, such as stationary and portable oxygen concentrators, alongside healthcare furnishings for long-term care settings. The company primarily sells its products through home medical equipment providers, residential care operators, and government health services, utilizing various distribution channels including retail and e-commerce. Invacare is committed to supporting individuals with diverse medical conditions, thereby promoting recovery and active lifestyles.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.

Starry, Inc. is an innovative internet company headquartered in Boston, Massachusetts, with operations in New York, New York. Founded in 2014, the company specializes in user-friendly Wi-Fi products and high-speed broadband internet services. Starry's flagship product, the Starry Station, is the world's first ambient touchscreen Wi-Fi router, designed to give users enhanced visibility and control over their home networks through an intuitive interface. The company utilizes advanced wideband hybrid-fiber fixed wireless technology to provide gigabit-capable internet without the constraints of bundles, data caps, or long-term contracts. Starry is committed to prioritizing customer needs, promoting digital equity, and ensuring privacy while delivering fast and reliable internet connectivity. Its products are available for purchase on the company's website and are also offered for pre-order through Amazon Launchpad.

CompoSecure specializes in designing and manufacturing premium financial cards, focusing on high-security requirements for both public and private sectors. The company utilizes advanced metal payment card technology alongside its Arculus security and authentication platform to create products that offer a premium user experience. These offerings not only enhance the accessibility and usability of assets but also ensure trust in transactions. CompoSecure's commitment to innovation and design enables it to deliver sophisticated solutions that meet the evolving needs of its clients.

Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.

BigBear.ai is a technology-focused company that specializes in decision intelligence solutions tailored for the national defense and intelligence sectors. The company offers a wide range of high-end capabilities, including artificial intelligence, machine learning, data science, and advanced analytics. Its services encompass offensive and defensive cybersecurity, data management, cloud solutions, digital engineering, and systems integration. BigBear.ai operates through two main segments: Cyber & Engineering and Analytics, serving various markets such as supply chains, logistics, autonomous systems, and cybersecurity. By leveraging its expertise in data and digital technologies, BigBear.ai aims to provide information superiority and robust decision support to its clients.

Lime is a transportation company that focuses on providing sustainable solutions for urban mobility by offering electric scooters and bike-sharing services. The company partners with cities to deploy a fleet of electric bikes and scooters equipped with GPS and self-activating locks, which allows users to access affordable and reliable transportation options. Lime aims to address the first- and last-mile transportation challenges, promoting environmentally friendly alternatives that help reduce carbon footprints. By encouraging a shift in transportation behavior, Lime seeks to empower future generations to contribute to a more sustainable planet.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Protalix Biotherapeutics is a biopharmaceutical company based in Karmiel, Israel, that specializes in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company is primarily known for its product Elelyso, a recombinant glucocerebrosidase enzyme approved for the treatment of Gaucher disease. Protalix is advancing a diverse pipeline, including PRX-102, which is in phase III clinical trials for Fabry disease, and OPRX-106, a therapeutic candidate for inflammatory bowel disease that has completed phase IIa trials for ulcerative colitis. Additionally, PRX-110, aimed at treating cystic fibrosis, and PRX-115, a treatment for gout, are also in development. Protalix has established partnerships with leading pharmaceutical companies, including Pfizer, and has a commercial presence in Brazil and other regions of Latin America. The company aims to target significant pharmaceutical markets with its innovative therapies for genetic and inflammatory disorders.

Inseego Corp. is a global provider of mobile, Internet of Things (IoT), and cloud solutions, catering to large enterprises, service providers, and small to medium-sized businesses. Headquartered in San Diego, California, the company specializes in designing and developing wireless hardware products that support 3G, 4G, and 5G technologies. Its offerings include fixed wireless routers, mobile hotspots, and IoT devices, all designed for various applications such as private LTE/5G networks, telematics, remote monitoring, and mobile broadband. Inseego's software-as-a-service (SaaS) solutions encompass fleet management, asset tracking, and monitoring services, marketed under the Ctrack brand. The company also provides device management services that help organizations optimize their wireless assets and reduce costs. With a strong presence in the United States and Canada, Inseego has established itself as a key player in the telematics and IoT sectors since its founding in 1996.

Emergent Payments, Inc. specializes in providing comprehensive payment solutions for merchants operating in high-growth markets across Latin America, Asia, India, and Eastern Europe. The company offers a robust hosted platform that supports various payment methods, including international cards, bank transfers, local cards, wallets, and mobile payments, alongside risk management and compliance services. Emergent Payments also delivers tailored implementation and managed services, ensuring clients receive technical support, fraud screening, and analytics optimized for their needs. Founded in 2007 and based in Palo Alto, California, the company has development centers in North Carolina and Shanghai, with additional international offices in locations such as Luxembourg, India, China, and South Korea. Emergent Payments, previously known as Live Gamer, Inc., rebranded in 2015 to focus on its core payments technology, enabling merchants to effectively navigate and thrive in emerging markets.

ACE*COMM Corporation was a provider of operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Their solutions were designed for wired, wireless, voice, data, multimedia, and Internet communication networks. Operating in various regions including the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific, ACE*COMM established strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. Founded in 1983 and headquartered in Gaithersburg, Maryland, the company focused on delivering essential tools for efficient network operations and management in the telecommunications industry.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

BravoSolution SpA specializes in supply management technology software and services aimed at enhancing procurement and sourcing processes. The company provides a range of solutions, including Spend Analysis to optimize savings and compliance, eSourcing for collaborative sourcing efforts, and supplier performance management tools. Its Contract Management service streamlines contract processes to ensure users realize savings from their negotiations. Notable products include BravoAlign, a cloud-based procurement alignment solution, and BravoAdvantage, a comprehensive platform that supports procurement initiatives from demand to contract. Additionally, BravoAdvantage Analytics offers data visualization tools, enabling procurement professionals to create intuitive reports and dashboards. BravoSolution also delivers collaboration services and government solutions related to spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates offices in multiple countries, including the United States, Brazil, and several European nations. As of late 2017, it functions as a subsidiary of JAGGAER, Inc.

Pharmacopeia, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutics for unmet medical needs. The company's internal program portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently in phase II clinical development for cardiovascular and renal diseases, such as hypertension and diabetic nephropathy. Additionally, PS178990, a muscle selective SARM agonist, is in phase I clinical development. Pharmacopeia also has a preclinical product, PS031291, aimed at treating multiple myeloma and inflammatory diseases like rheumatoid arthritis, as well as JAK3 inhibitors targeting T-cell and cytokine mediated dermatologic and ocular conditions, including psoriasis and dry eye. The company has formed strategic alliances with several pharmaceutical firms, enhancing its research and development capabilities. Founded in 1993 and based in Cranbury, New Jersey, Pharmacopeia was previously known as Pharmacopeia Drug Discovery, Inc. and became a subsidiary of Ligand Pharmaceuticals Inc. in 2008.

Lexar is a well-established global brand specializing in memory solutions, with over 20 years of experience in the industry. The company offers a diverse range of products, including memory cards, USB flash drives, card readers, and solid-state drives, catering to markets such as gaming, professional photography, and personal data storage. Lexar emphasizes quality and reliability, conducting extensive testing on its products in specialized labs equipped with over 1,100 digital devices to ensure optimal performance and compatibility. Lexar's products are widely available through major retail and online stores around the world. For further information and support, consumers can visit the company's official website.

Strategic Data Corp. is an interactive technology company focused on optimizing the delivery of online advertising. Founded in 1999, SDC has specialized in developing display ad serving and yield-optimization technology that significantly increases the revenue for its clients. Currently, it operates as a subsidiary of Fox Interactive Media.